Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Originally published in Science Express on 19 September 2002
Science 25 October 2002:
Vol. 298. no. 5594, pp. 850 - 854
DOI: 10.1126/science.1076514
Prev | Table of Contents

Reports

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Mark E. Dudley,1 John R. Wunderlich,1 Paul F. Robbins,1 James C. Yang,1 Patrick Hwu,1 Douglas J. Schwartzentruber,1 Suzanne L. Topalian,1 Richard Sherry,1 Nicholas P. Restifo,1 Amy M. Hubicki,1 Michael R. Robinson,2 Mark Raffeld,3 Paul Duray,3 Claudia A. Seipp,1 Linda Rogers-Freezer,1 Kathleen E. Morton,1 Sharon A. Mavroukakis,1 Donald E. White,1 Steven A. Rosenberg1*

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen. This approach resulted in the persistent clonal repopulation of T cells in those cancer patients, with the transferred cells proliferating in vivo, displaying functional activity, and trafficking to tumor sites. This led to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.

1 Surgery Branch, National Cancer Institute;
2 National Eye Institute;
3 Laboratory of Pathology, National Cancer Institute; National Institutes of Health, Bethesda, MD 20902, USA.
*   To whom correspondence should be addressed. E-mail: SAR{at}nih.gov

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Requirements for Effective Antitumor Responses of TCR Transduced T Cells.
M. A. de Witte, A. Jorritsma, A. Kaiser, M. D. van den Boom, M. Dokter, G. M. Bendle, J. B. A. G. Haanen, and T. N. M. Schumacher (2008)
J. Immunol. 181, 5128-5136
   Abstract »    Full Text »    PDF »
Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity.
Y. H. Kim, B. K. Choi, K. H. Kim, S. W. Kang, and B. S. Kwon (2008)
Cancer Res. 68, 7264-7269
   Abstract »    Full Text »    PDF »
CD8+ T Cells Targeting a Single Immunodominant Epitope are Sufficient for Elimination of Established SV40 T Antigen-Induced Brain Tumors.
A. M. Tatum, L. M. Mylin, S. J. Bender, M. A. Fischer, B. A. Vigliotti, M. J. Tevethia, S. S. Tevethia, and T. D. Schell (2008)
J. Immunol. 181, 4406-4417
   Abstract »    Full Text »    PDF »
Cancer immunotherapy..
S. A. Rosenberg, M. E. Dudley, N. P. Restifo, R. Prestwich, R. Vile, A. Melcher, and L. M. Weiner (2008)
N. Engl. J. Med. 359, 1072
   Full Text »    PDF »
Overcoming obstacles to the effective immunotherapy of human cancer.
S. A. Rosenberg (2008)
PNAS 105, 12643-12644
   Full Text »    PDF »
Advances in tumour immunotherapy.
J. King, J. Waxman, and H. Stauss (2008)
QJM 101, 675-683
   Abstract »    Full Text »    PDF »
Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo.
H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy (2008)
J. Immunol. 181, 3449-3455
   Abstract »    Full Text »    PDF »
TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation.
M. A. de Witte, G. M. Bendle, M. D. van den Boom, M. Coccoris, T. D. Schell, S. S. Tevethia, H. van Tinteren, E. M. Mesman, J.-Y. Song, and T. N. M. Schumacher (2008)
J. Immunol. 181, 2563-2571
   Abstract »    Full Text »    PDF »
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?.
C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert (2008)
Clin. Cancer Res. 14, 5242-5249
   Abstract »    Full Text »    PDF »
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer.
H. L. Kaufman, H.-J. Lenz, J. Marshall, D. Singh, C. Garett, C. Cripps, M. Moore, M. von Mehren, R. Dalfen, W. J. Heim, et al. (2008)
Clin. Cancer Res. 14, 4843-4849
   Abstract »    Full Text »    PDF »
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas.
C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. (2008)
Clin. Cancer Res. 14, 4850-4858
   Abstract »    Full Text »    PDF »
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
G. Willimsky, M. Czeh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein (2008)
J. Exp. Med. 205, 1687-1700
   Abstract »    Full Text »    PDF »
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1.
N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee (2008)
N. Engl. J. Med. 358, 2698-2703
   Abstract »    Full Text »    PDF »
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer.
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al. (2008)
Cancer Res. 68, 4893-4901
   Abstract »    Full Text »    PDF »
CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4.
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard (2008)
J. Immunol. 180, 8135-8145
   Abstract »    Full Text »    PDF »
PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro.
W. Yang, P. W. Chen, H. Li, H. Alizadeh, and J. Y. Niederkorn (2008)
Invest. Ophthalmol. Vis. Sci. 49, 2518-2525
   Abstract »    Full Text »    PDF »
Noninvasive Imaging of Cell-Mediated Therapy for Treatment of Cancer.
E. J. Akins and P. Dubey (2008)
J. Nucl. Med. 49, 180S-195S
   Abstract »    Full Text »    PDF »
Long-Term Functionality of TCR-Transduced T Cells In Vivo.
M. Coccoris, E. Swart, M. A. de Witte, J. W. J. van Heijst, J. B. A. G. Haanen, K. Schepers, and T. N. M. Schumacher (2008)
J. Immunol. 180, 6536-6543
   Abstract »    Full Text »    PDF »
Searching for factors to improve the antileukemic effect of donor lymphocyte infusion.
S. Maury, C. Cordonnier, M. Kuentz, D. Klatzmann, and J. L. Cohen (2008)
Blood 111, 5256
   Full Text »    PDF »
Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma.
J. A. Sosman, C. Carrillo, W. J. Urba, L. Flaherty, M. B. Atkins, J. I. Clark, J. Dutcher, K. A. Margolin, J. Mier, J. Gollob, et al. (2008)
J. Clin. Oncol. 26, 2292-2298
   Abstract »    Full Text »    PDF »
Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape.
O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach (2008)
Cancer Res. 68, 3450-3457
   Abstract »    Full Text »    PDF »
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions.
P. F. Robbins, Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. (2008)
J. Immunol. 180, 6116-6131
   Abstract »    Full Text »    PDF »
An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease.
M. A. de Witte, A. Jorritsma, E. Swart, K. C. Straathof, K. de Punder, J. B. A. G. Haanen, C. M. Rooney, and T. N. M. Schumacher (2008)
J. Immunol. 180, 6365-6373
   Abstract »    Full Text »    PDF »
Interleukin-15/Interleukin-15R{alpha} Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells.
M. Epardaud, K. G. Elpek, M. P. Rubinstein, A.-r. Yonekura, A. Bellemare-Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley (2008)
Cancer Res. 68, 2972-2983
   Abstract »    Full Text »    PDF »
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer.
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen (2008)
Cancer Res. 68, 2455-2462
   Abstract »    Full Text »    PDF »
Induction of Antitumor Immune Response by Homeostatic Proliferation and CD28 Signaling.
T. Suzuki, S. Ogawa, K. Tanabe, H. Tahara, R. Abe, and H. Kishimoto (2008)
J. Immunol. 180, 4596-4605
   Abstract »    Full Text »    PDF »
Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs.
A. Machlenkin, R. Uzana, S. Frankenburg, G. Eisenberg, L. Eisenbach, J. Pitcovski, R. Gorodetsky, A. Nissan, T. Peretz, and M. Lotem (2008)
Cancer Res. 68, 2006-2013
   Abstract »    Full Text »    PDF »
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma.
M. Fujita, X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada (2008)
J. Immunol. 180, 2089-2098
   Abstract »    Full Text »    PDF »
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky (2008)
Blood 111, 2112-2121
   Abstract »    Full Text »    PDF »
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study.
A. B. Heimberger, W. Sun, S. F. Hussain, M. Dey, L. Crutcher, K. Aldape, M. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, et al. (2008)
Neuro-oncol 10, 98-103
   Abstract »    Full Text »    PDF »
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
E. Kieback, J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert (2008)
PNAS 105, 623-628
   Abstract »    Full Text »    PDF »
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer.
A. Barber, T. Zhang, and C. L. Sentman (2008)
J. Immunol. 180, 72-78
   Abstract »    Full Text »    PDF »
Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition.
W. H.D. Hallett, E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy (2008)
J. Immunol. 180, 163-170
   Abstract »    Full Text »    PDF »
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.
Y. Li and C. Yee (2008)
Blood 111, 229-235
   Abstract »    Full Text »    PDF »
Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer.
T. Kottke, L. Sanchez-Perez, R. M. Diaz, J. Thompson, H. Chong, K. Harrington, S. K. Calderwood, J. Pulido, N. Georgopoulos, P. Selby, et al. (2007)
Cancer Res. 67, 11970-11979
   Abstract »    Full Text »    PDF »
Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells.
M. Moeller, M. H. Kershaw, R. Cameron, J. A. Westwood, J. A. Trapani, M. J. Smyth, and P. K. Darcy (2007)
Cancer Res. 67, 11428-11437
   Abstract »    Full Text »    PDF »
CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer.
Y. Kiniwa, Y. Miyahara, H. Y. Wang, W. Peng, G. Peng, T. M. Wheeler, T. C. Thompson, L. J. Old, and R.-F. Wang (2007)
Clin. Cancer Res. 13, 6947-6958
   Abstract »    Full Text »    PDF »
CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism.
T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson (2007)
Clin. Cancer Res. 13, 7172-7180
   Abstract »    Full Text »    PDF »
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma.
A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al. (2007)
Blood 110, 3564-3572
   Abstract »    Full Text »    PDF »
How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies.
K. Leon, K. Garcia, J. Carneiro, and A. Lage (2007)
J. Immunol. 179, 5659-5668
   Abstract »    Full Text »    PDF »
Cross-presentation of glycolipid from tumor cells loaded with {alpha}-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.
K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S.-i. Fujii (2007)
J. Exp. Med. 204, 2641-2653
   Abstract »    Full Text »    PDF »
Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors.
A. U. van Lent, M. Nagasawa, M. M. van Loenen, R. Schotte, T. N. M. Schumacher, M. H. M. Heemskerk, H. Spits, and N. Legrand (2007)
J. Immunol. 179, 4959-4968
   Abstract »    Full Text »    PDF »
Warrior, miscreant, suicide: making better killers.
M. E. Dudley (2007)
Blood 110, 2781-2782
   Full Text »    PDF »
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
C. Quintarelli, J. F. Vera, B. Savoldo, G. M. P. Giordano Attianese, M. Pule, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti (2007)
Blood 110, 2793-2802
   Abstract »    Full Text »    PDF »
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies.
J. N. Kochenderfer and R. E. Gress (2007)
Experimental Biology and Medicine 232, 1130-1141
   Abstract »    Full Text »    PDF »
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells.
S. Liu, G. Lizee, Y. Lou, C. Liu, W. W. Overwijk, G. Wang, and P. Hwu (2007)
Int. Immunol. 19, 1213-1221
   Abstract »    Full Text »    PDF »
4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy.
H. Zhang, K. M. Snyder, M. M. Suhoski, M. V. Maus, V. Kapoor, C. H. June, and C. L. Mackall (2007)
J. Immunol. 179, 4910-4918
   Abstract »    Full Text »    PDF »
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.
J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al. (2007)
Blood 110, 2761-2763
   Abstract »    Full Text »    PDF »
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy.
G. Lizee, M. A. Cantu, and P. Hwu (2007)
Clin. Cancer Res. 13, 5250-5255
   Abstract »    Full Text »    PDF »
Toll-like Receptors in Tumor Immunotherapy.
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. (2007)
Clin. Cancer Res. 13, 5280-5289
   Abstract »    Full Text »    PDF »
Gene-Engineered Varicella-Zoster Virus Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function.
S. Landmeier, B. Altvater, S. Pscherer, B. R. Eing, J. Kuehn, C. M. Rooney, H. Juergens, and C. Rossig (2007)
Cancer Res. 67, 8335-8343
   Abstract »    Full Text »    PDF »
Decreased Tumor Surveillance after Adoptive T-Cell Therapy.
M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein (2007)
Cancer Res. 67, 7467-7476
   Abstract »    Full Text »    PDF »
Cross-Talk between T Cells and Innate Immune Cells Is Crucial for IFN-{gamma}-Dependent Tumor Rejection.
Z. Li, F. Pradera, T. Kammertoens, B. Li, S. Liu, and Z. Qin (2007)
J. Immunol. 179, 1568-1576
   Abstract »    Full Text »    PDF »
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.
M. J. Pittet, J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder (2007)
PNAS 104, 12457-12461
   Abstract »    Full Text »    PDF »
Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells.
F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker (2007)
J. Immunol. 179, 845-853
   Abstract »    Full Text »    PDF »
Immunologic Approaches to Ovarian Cancer Treatment.
P. Sabbatini and K. Odunsi (2007)
J. Clin. Oncol. 25, 2884-2893
   Abstract »    Full Text »    PDF »
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.
J. N. Kochenderfer, J. L. Simpson, C. D. Chien, and R. E. Gress (2007)
Blood 110, 450-460
   Abstract »    Full Text »    PDF »
CD4 cells can be more efficient at tumor rejection than CD8 cells.
A. Perez-Diez, N. T. Joncker, K. Choi, W. F. N. Chan, C. C. Anderson, O. Lantz, and P. Matzinger (2007)
Blood 109, 5346-5354
   Abstract »    Full Text »    PDF »
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor.
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher (2007)
J. Immunol. 178, 6752-6760
   Abstract »    Full Text »    PDF »
Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma.
J. Michalek, I. Kocak, V. Fait, J. Zaloudik, and R. Hajek (2007)
J. Immunol. 178, 6789-6795
   Abstract »    Full Text »    PDF »
Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death.
G. Friedlein, F. El Hage, I. Vergnon, C. Richon, P. Saulnier, Y. Lecluse, A. Caignard, L. Boumsell, G. Bismuth, S. Chouaib, et al. (2007)
J. Immunol. 178, 6821-6827
   Abstract »    Full Text »    PDF »
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
S. Loeser, K. Loser, M. S. Bijker, M. Rangachari, S. H. van der Burg, T. Wada, S. Beissert, C. J.M. Melief, and J. M. Penninger (2007)
J. Exp. Med. 204, 879-891
   Abstract »    Full Text »    PDF »
Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond.
C. J. Cohen, Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan (2007)
Cancer Res. 67, 3898-3903
   Abstract »    Full Text »    PDF »
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma.
N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia (2007)
Clin. Cancer Res. 13, 2246-2253
   Abstract »    Full Text »    PDF »
Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling.
Y. Zhao, M. R. Parkhurst, Z. Zheng, C. J. Cohen, J. P. Riley, L. Gattinoni, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan (2007)
Cancer Res. 67, 2425-2429
   Abstract »    Full Text »    PDF »
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy.
H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al. (2007)
Cancer Res. 67, 2872-2880
   Abstract »    Full Text »    PDF »
Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta.
V. C. Liu, L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee (2007)
J. Immunol. 178, 2883-2892
   Abstract »    Full Text »    PDF »
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis.
M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al. (2007)
J. Immunol. 178, 3307-3315
   Abstract »    Full Text »    PDF »
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.
A. Boissonnas, L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena (2007)
J. Exp. Med. 204, 345-356
   Abstract »    Full Text »    PDF »
Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer.
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng (2007)
Cancer Res. 67, 1291-1298
   Abstract »    Full Text »    PDF »
The Varicellovirus-Encoded TAP Inhibitor UL49.5 Regulates the Presentation of CTL Epitopes by Qa-1b1.
T. van Hall, S. Laban, D. Koppers-Lalic, J. Koch, C. Precup, P. Asmawidjaja, R. Offringa, and E. J. H. J. Wiertz (2007)
J. Immunol. 178, 657-662
   Abstract »    Full Text »    PDF »
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration.
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al. (2007)
Clin. Cancer Res. 13, 644-653
   Abstract »    Full Text »    PDF »
Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-Cell Therapy.
U. Thanarajasingam, L. Sanz, R. Diaz, J. Qiao, L. Sanchez-Perez, T. Kottke, J. Thompson, J. Chester, and R. G. Vile (2007)
Cancer Res. 67, 300-308
   Abstract »    Full Text »    PDF »
Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy.
S. R. Riddell (2007)
Hematology 2007, 250-256
   Abstract »    Full Text »    PDF »
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.
M. H. M. Heemskerk, R. S. Hagedoorn, M. A. W. G. van der Hoorn, L. T. van der Veken, M. Hoogeboom, M. G. D. Kester, R. Willemze, and J. H. F. Falkenburg (2007)
Blood 109, 235-243
   Abstract »    Full Text »    PDF »
Synergism between CpG-Containing Oligodeoxynucleotides and IL-2 Causes Dramatic Enhancement of Vaccine-Elicited CD8+ T Cell Responses.
J. N. Kochenderfer, C. D. Chien, J. L. Simpson, and R. E. Gress (2006)
J. Immunol. 177, 8860-8873
   Abstract »    Full Text »    PDF »
Enhancement of Immunologic Tumor Regression by Intratumoral Administration of Dendritic Cells in Combination with Cryoablative Tumor Pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation.
M. Udagawa, C. Kudo-Saito, G. Hasegawa, K. Yano, A. Yamamoto, M. Yaguchi, M. Toda, I. Azuma, T. Iwai, and Y. Kawakami (2006)
Clin. Cancer Res. 12, 7465-7475
   Abstract »    Full Text »    PDF »
IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase.
G. F. Weber, F. C. Gaertner, W. Erl, K.-P. Janssen, B. Ble